Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). The Company reported positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials, the MARINE trial (investigation of AMR101 as a treatment for patients with very high triglycerides [>500 mg/dL]), as reported on November 29, 2010 and the ANCHOR trial (investigation of AMR101 for the treatment of patients on statin therapy with high triglycerides [≥200 and <500mg/dL]) with mixed dyslipidemia), as reported on April 18, 2011. Amarin submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2011 requesting approval to market and sell AMR101 for the indication being studied in the MARINE trial in the United States. The submission is based on the entire data set from the Company's AMR101 development program, including safety and efficacy data from the Phase 3 MARINE and ANCHOR studies.

The MARINE and ANCHOR trials were conducted under separate Special Protocol Assessment (SPA) agreements with the FDA. Amarin also has next-generation lipid candidates under evaluation for preclinical development.

Market Listings For Amarin Stock

Amarin is listed on the Nasdaq capital market (ticker: AMRN).